153 related articles for article (PubMed ID: 2876091)
1. Effects of BMY 14802, a potential antipsychotic drug, on rat brain dopaminergic function.
Matthews RT; McMillen BA; Sallis R; Blair D
J Pharmacol Exp Ther; 1986 Oct; 239(1):124-31. PubMed ID: 2876091
[TBL] [Abstract][Full Text] [Related]
2. Electrophysiological effects of BMY 14802, a new potential antipsychotic drug, on midbrain dopamine neurons in the rat: acute and chronic studies.
Wachtel SR; White FJ
J Pharmacol Exp Ther; 1988 Jan; 244(1):410-6. PubMed ID: 2891845
[TBL] [Abstract][Full Text] [Related]
3. CI-943, a potential antipsychotic agent. II. Neurochemical effects.
Pugsley TA; Coughenour LL; Myers SL; Shih YH; Courtland GG; Berghoff W; Stewart SF
J Pharmacol Exp Ther; 1989 Oct; 251(1):113-22. PubMed ID: 2571713
[TBL] [Abstract][Full Text] [Related]
4. Effects of a fluorinated pyrimidinedione anti-cancer drug, 5-fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione (FT), and related compounds on nigro-striatal dopaminergic neurons in the central nervous system.
Toide K; Unemi N; Segawa T
Arch Int Pharmacodyn Ther; 1985 Mar; 274(1):111-24. PubMed ID: 3925907
[TBL] [Abstract][Full Text] [Related]
5. Further characterization of the effects of BMY 14802 on dopamine neuronal activity.
Zhang J; Chiodo LA; Freeman AS
Synapse; 1993 Dec; 15(4):276-84. PubMed ID: 7908761
[TBL] [Abstract][Full Text] [Related]
6. Regulation of dopamine synthesis in the medial prefrontal cortex is mediated by release modulating autoreceptors: studies in vivo.
Galloway MP; Wolf ME; Roth RH
J Pharmacol Exp Ther; 1986 Mar; 236(3):689-98. PubMed ID: 3081705
[TBL] [Abstract][Full Text] [Related]
7. Influence of supidimide on brain neurotransmitter systems of rats and mice.
Hennies HH; Günzler WA; Flohé L
Arzneimittelforschung; 1984; 34(11):1471-80. PubMed ID: 6084511
[TBL] [Abstract][Full Text] [Related]
8. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
[TBL] [Abstract][Full Text] [Related]
9. CI-943, a potential antipsychotic agent. III. Evaluation of effects on dopamine neuronal activity.
Meltzer LT; Christoffersen CL; Heffner TG; Freeman AS; Chiodo LA
J Pharmacol Exp Ther; 1989 Oct; 251(1):123-30. PubMed ID: 2571714
[TBL] [Abstract][Full Text] [Related]
10. Pimozide: delayed onset of action at rat striatal pre- and postsynaptic dopamine receptors.
McMillen BA; German DC; Sanghere MK; Warnack W; Shore PA
J Pharmacol Exp Ther; 1980 Oct; 215(1):150-5. PubMed ID: 6109013
[TBL] [Abstract][Full Text] [Related]
11. Differential dose- and time-dependent effects of molindone on dopamine neurons of rat brain: mediation by irreversible inhibition of monoamine oxidase.
Meller E; Friedman E
J Pharmacol Exp Ther; 1982 Mar; 220(3):609-15. PubMed ID: 6121048
[TBL] [Abstract][Full Text] [Related]
12. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
Rugsley TA; Davis MD; Akunne HC; Cooke LW; Whetzel SZ; MacKenzie RG; Shih YH; van Leeuwen DH; DeMattos SB; Georgic LM
J Pharmacol Exp Ther; 1995 Aug; 274(2):898-911. PubMed ID: 7636753
[TBL] [Abstract][Full Text] [Related]
13. Acute and subchronic effects of MJ-13859, a potential antipsychotic drug, on rat brain dopaminergic function.
McMillen BA
J Pharmacol Exp Ther; 1985 May; 233(2):369-75. PubMed ID: 2987476
[TBL] [Abstract][Full Text] [Related]
14. SCH23390 effects on apomorphine-induced responses of nigral dopaminergic neurons.
Napier TC; Givens BS; Schulz DW; Bunney BS; Breese GR; Mailman RB
J Pharmacol Exp Ther; 1986 Mar; 236(3):838-45. PubMed ID: 3512819
[TBL] [Abstract][Full Text] [Related]
15. Acute effects of sigma ligands on the electrophysiological activity of rat nigrostriatal and mesoaccumbal dopaminergic neurons.
Zhang J; Chiodo LA; Wettstein JG; Junien JL; Freeman AS
Synapse; 1992 Aug; 11(4):267-78. PubMed ID: 1323882
[TBL] [Abstract][Full Text] [Related]
16. Regulation of dopamine synthesis in the medial prefrontal cortex: studies in brain slices.
Wolf ME; Galloway MP; Roth RH
J Pharmacol Exp Ther; 1986 Mar; 236(3):699-707. PubMed ID: 2869140
[TBL] [Abstract][Full Text] [Related]
17. BMY-14802, a sigma ligand and potential antipsychotic drug, reverses amphetamine-induced changes in neostriatal single-unit activity in freely moving rats.
Wang Z; Haracz JL; Rebec GV
Synapse; 1992 Dec; 12(4):312-21. PubMed ID: 1361249
[TBL] [Abstract][Full Text] [Related]
18. Antipsychotic drug effects on dopamine and serotonin receptors: in vitro binding and in vivo turnover studies.
Bacopoulos NG
J Pharmacol Exp Ther; 1981 Dec; 219(3):708-14. PubMed ID: 6170752
[TBL] [Abstract][Full Text] [Related]
19. Neurochemical studies on central dopamine neurons--regional characterization of dopamine turnover.
Hallman H; Jonsson G
Med Biol; 1984; 62(3):198-209. PubMed ID: 6492900
[TBL] [Abstract][Full Text] [Related]
20. Comparative chronic effects of buspirone or neuroleptics on rat brain dopaminergic neurotransmission.
McMillen BA
J Neural Transm; 1985; 64(1):1-12. PubMed ID: 2866230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
